Osimertinib alone or with chemo for EGFR-mutant lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests whether osimertinib alone is as good as osimertinib plus chemotherapy for lung cancers that have a specific EGFR mutation. It may help by improving how well the cancer responds and slows growth in people with metastatic non-small cell lung cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 years or older
- Have metastatic non-small cell lung cancer that has tested positive for an EGFR activating mutation (from a tumor biopsy, fluid sample, or blood test)
- Start of osimertinib: either you have not taken an EGFR-targeting pill before, or if you took osimertinib recently (within about 3 weeks) it must be before any other chemotherapy for metastatic disease (adjuvant chemo >6 months ago is allowed)
- Have at least one measurable tumor spot on scans that was not previously treated with radiation
- Be able to take swallowed pills, and have a heart/lung status the study team considers safe (Karnofsky performance score at least 70%)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies osimertinib in people with advanced or metastatic lung cancer that has specific EGFR gene changes. It aims to see how well this targeted medicine can control the cancer when surgery or radiotherapy won’t work.
This study compares two standard treatments for advanced lung cancer with an EGFR mutation: osimertinib alone versus osimertinib plus chemotherapy. It aims to see which approach works better and is not a trial of a new drug, so you can receive usual care while contributing data.
This study tests adding chemotherapy (pemetrexed and carboplatin) to the targeted drug osimertinib (Tagrisso) for people with a specific type of advanced lung cancer (EGFR-mutated adenocarcinoma) that is not controlled well by osimertinib alone. The goal is to see if the combination helps people live longer or better.
This trial tests a combination of two drugs, osimertinib and etoposide, for people with a specific type of advanced lung cancer (EGFR-mutant NSCLC) that has stopped responding well to osimertinib alone. It may help if your cancer is stable or slowly getting worse on osimertinib as your first treatment.
This Phase 2 study tests a treatment sequence starting with osimertinib, then using chemotherapy after it. It is meant for people with EGFR-mutated advanced lung cancer whose disease has come back or progressed, including a “rechallenge” attempt with osimertinib.
This Phase 3 trial tests whether starting osimertinib with or without bevacizumab helps people with advanced EGFR-mutant lung cancer live longer and control the cancer better. Your EGFR mutation test result and past treatments are key to whether you can join.
Hear when a new Metastatic Non-small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.